Havrdova, Eva, Belova, Anna, Goloborodko, Alla, Tisserant, Anne, Wright, Andrew, Wallstroem, Erik, garren, hideki, Maguire, Paul and Johns, Donald (2016) Activity of secukinumab, an anti‒IL-17A antibody, on brain lesions in RRMS: Results from a randomized, proof-of-concept study. Journal of Neurology.

Abstract

We assessed the effect of secukinumab on numbers of new active brain magnetic resonance imaging (MRI) lesions in subjects with relapsing-remitting multiple sclerosis (MS). Subjects (n=73) were randomized 1:1 to secukinumab 10 mg/kg or placebo by IV infusion at Weeks 0, 2, 4, 8, 12, 16, and 20. Compared with placebo, secukinumab reduced combined unique active lesions (CUAL) observed on 4-weekly MRI from Week 4 to 24 by 49% (95% CI, -10% to 77%; P=0.087) and cumulative new gadolinium-enhancing T1 lesions by 67% (31% to 84%, P=0.003). CUAL reductions were progressively greater from Week 4 (1%) to Week 16 (49%) and persisted until end-study (50%). There were no serious adverse events (SAEs); the AE rate was comparable to placebo (53% versus 49%), although infection was somewhat more frequent (37% versus 23%). Secukinumab was associated with reduced MRI lesion activity and was safe/well tolerated, supporting further clinical development in MS.

Item Type:	Article
Keywords:	RRMS, multiple sclerosis, neuroscience, AIN457, sekukinumab,
Date Deposited:	10 May 2016 23:45
Last Modified:	10 May 2016 23:45
URI:	https://oak.novartis.com/id/eprint/22380